| 02.10 16:31 | dpa-AFX: JNJ's Erleada Shows Statistically Significant Overall Survival In Metastatic Prostate Cancer |
| 02.10 15:03 | dpa-AFX: *J&J : ERLEADA SHOWS SIGNIFICANT SURVIVAL BENEFITS OVER ENZALUTAMIDE IN METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER |
| 30.09 15:04 | dpa-AFX: Johnson & Johnson Expands Roll-out Of TECNIS Odyssey IOL |
| 30.09 14:11 | dpa-AFX: *J&J LAUNCHES TECNIS ODYSSEY LENS FOR PRECISE VISION AT EVERY DISTANCE AND LIGHTING |
| 28.09 09:02 | dpa-AFX: J&J : DARZALEX FASPRO Quadruplet Regimen Improves MRD Negativity In Newly Diagnosed Multiple Myeloma |
| 28.09 08:14 | dpa-AFX: J&J : Phase 3 Trial Results Show CARVYKTI Extends Overall Survival In Relapsed Multiple Myeloma |
| 27.09 22:26 | dpa-AFX: Johnson & Johnson Says Darzalex Regimens Show Meaningful Responses In Patients With Multiple Myeloma |
| 27.09 14:49 | dpa-AFX: Johnson & Johnson Reports New Data From Phase 1b TRIMM-2 Study |
| 27.09 14:30 | dpa-AFX: J&J Reports Data From Investigational Phase 1b RedirecTT-1 Study |
| 27.09 14:10 | dpa-AFX: *J&J : TALVEY AND TECVAYLI SHOW HIGH RESPONSE RATES IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA |
| 27.09 14:07 | dpa-AFX: *JOHNSON & JOHNSON ANNOUNCES PHASE 1B TRIMM-2 RESULTS EVALUATING TALVEY WITH DARZALEX FASPRO |
| 27.09 09:34 | EU-Zulassung für Stelara-Biosimilar von Formycon und Fresenius Kabi |
| 21.09 07:21 | dpa-AFX: J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims |
| 20.09 14:04 | dpa-AFX: Janssen-Cilag Reports CHMP Recommendation For Daratumumab |
| 20.09 13:43 | dpa-AFX: *J&J : DARZALEX QUADRUPLET REGIMEN GETS POSITIVE CHMP OPINION FOR NEWLY DIAGNOSED MYELOMA PATIENTS |
| 20.09 02:47 | dpa-AFX: FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy |
| 16.09 09:33 | dpa-AFX: Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study |
| 16.09 08:55 | dpa-AFX: *J&J ANNOUNCES INTERIM DATA FROM PHASE 2 SUNRISE-4 STUDY OF TAR-200 COMBINATION IN MUSCLE-INVASIVE BLADDER CANCER |
| 15.09 10:15 | dpa-AFX: J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer |
| 14.09 16:39 | dpa-AFX: J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer |
|
|
